Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialKausik K Ray, Robert A Harrington, J. Wouter Jukema et al.|The Lancet Diabetes & Endocrinology|2019Cited by 330
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolZeljko Reiner, Gregory G. Schwartz, Vera A. Bittner et al.|Journal of the American College of Cardiology|2021Cited by 143
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of AlirocumabEmil Hagström, Patricio López‐Jaramillo, Philippe Gabríel Steg et al.|Circulation|2022Cited by 123
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab TreatmentGregory G. Schwartz, Nicolas Danchin, Michael Szarek et al.|Diabetes Care|2021Cited by 39
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G. Goodman, Ivan Pećin, Philippe Gabríel Steg et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2024Cited by 24